This application is filed claiming priority from co-pending U.S. Provisional application Ser. Nos. 60/231,122 filed Sep. 8, 2000 and 60/290,728 filed May 14, 2001.
Priority Data
Jul 28, 2000 [GB] 0018656 Mar 15, 2001 [GB] 0106464
Compounds of the formula (I): ##STR1## wherein R.sup.1, R.sup.2, R.sup.4 and R.sup.13 are as defined or a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).
A process for the preparation of Compounds of the formula (1): ##STR00001## wherein R.sup.1, R.sup.2, R.sup.4 and R.sup.13 are as defined or a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiestbrase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).
Compounds of formula (I), ##STR00001## or pharmaceutically acceptable derivatives thereof, wherein: Het represents 2-pyridinyl or 2-pyrimidinyl; R.sup.1 represents H, C.sub.1-3 alkyl or a nitrogen-containing heterocyclic ring having 5 or 6 ring atoms; R.sup.2 represents H, benzyl or C.sub.1-3 alkyl; and R.sup.3 represents H, methyl, methoxy or chloro; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.
